Sarbanes-Oxley exemption
This article was originally published in The Gray Sheet
Executive Summary
AdvaMed and the Medical Device Manufacturer's Association join a coalition of technology associations in an April 3 letter urging the Securities and Exchange Commission to adopt a draft guidance that would ease external auditing requirements for public companies with annual fiscal revenues under $250 mil. The letter states that "this approach will begin to address the disproportionate cost burdens of section 404 requirements that continue to hamper smaller companies' ability to invest in research and development, to gain access to public capital markets, and to remain competitive." Since it was enacted in 2002, the Sarbanes-Oxley Act has required all public companies to pay to have their internal controls checked by an external auditor (1"The Gray Sheet" Dec. 19, 2005, p. 11)...
You may also be interested in...
Panel Says Small Public Firms Should Be Exempt From External Auditing Law
A Securities & Exchange Commission committee voiced approval for changes to the Sarbanes-Oxley Act that could save small device firms millions of dollars spent to comply with external auditing requirements
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.